Mylan launches cabergoline tablets
PITTSBURGH — Mylan has launched a generic drug for treating a condition that causes heightened levels of the protein prolactin in the blood, the company said Thursday.
Mylan announced the launch of cabergoline tablets in the 0.5-mg strength, used for treating hyperprolactinemic disorders.
Various versions of the drug had sales of about $41.67 million during the 12-month period ending in September, according to IMS Health.
Mylan completes acquisition of Agila from Strides Arcolab
PITTSBURGH — Mylan has completed its acquisition of the injectables business of Strides Arcolab, a deal worth nearly $2 billion, the drug maker said.
Mylan said the acquisition of Agila could cost up to $1.75 billion, including a $250 million contingent consideration. As part of the acquisition, Mylan will gain full commercialization rights for most of Agila’s U.S. portfolio of experimental and marketed products, including cancer drugs, as well as significant product rights in Canada, Australia, Brazil, Japan and South Korea.
"The acquisition of Agila will create a global injectables leader, expanding and strengthening Mylan’s existing injectables platform and portfolio and providing Mylan entry into exciting new geographic markets," Mylan CEO Heather Bresch said. "We believe we can generate significant growth from this business as we maximize the capabilities of this platform and accelerate the many untapped opportunities we see ahead."
Pharmacy Compounding Accreditation Board seeks new executive director
WASHINGTON — The Pharmacy Compounding Accreditation Board is looking for a new executive director following the departure of Joe Cabaleiro, the group said Wednesday.
The formal search will start in January, and the new executive director will oversee accreditation programs for compounding pharmacies and lead compounding initiatives to enhance patient care and improve quality practices. Interested parties may contact National Community Pharmacists Association chief of staff Beverly Martin.
"Pharmacist compounding services, the art of customizing medications for a patient’s unique healthcare needs based on a prescriber’s order, continues to be in high demand," PCAB president Douglas Hoey said; Hoey is also CEO of the NCPA. "To meet the high standards set forth for PCAB accreditation, an accredited compounding pharmacy has proven that it is providing a valuable healthcare service to its community."